Effects of the colour of curatives, of previous experiences and expectations, and of personality variables upon the generation of non-specific adverse (nocebo) effects of drugs were studied in a double-blind, randomized experiment. Thirty-eight female undergraduate students completed questionnaires (experiences, expectancies, state anxiety (STAI-S), dispositional optimism (LOT-R), somatosensory amplification (SSAS), somatic symptoms (PHQ-15)), then randomly ingested a white or red NSAID tablet (200-mg ibuprofen), and monitored themselves for 10 min for symptoms. According to a regression analysis, predictors of experienced symptoms were personal experiences with and expectations of side effects, and SSAS and PHQ-15 scores. Regarding the 14 monitored symptoms, significant differences between red and white tablets were found in five cases (irritability/agitation, palpitation vs. drowsiness, blurred vision, heartburn). Better understanding of personality and situational factors causing nocebo effects could help to identify and to avoid them.
[1]. H. Benson R. Friedman 1996 Harnessing the power of the placebo effect and renaming it “remembered wellness” Annu. Rev. Med. 47 193–199.
[2]. R. R. Bootzin E. T. Bailey 2005 Understanding placebo, nocebo, and iatrogenic treatment effects J. Clin. Psychol. 61 7 871–880.
[3]. M. M. Reidenberg D. T. Lowenthal 1968 Adverse nondrug reactions New Engl. J. Med. 279 13 678–679.
[4]. P. Rosenzweig S. Brohier A. Zipfel 1995 The placebo effect in healthy volunteers: influence of experimental conditions on physiological parameters during phase I studies Br. J. Clin. Pharmacol. 39 6 657–664.
[5]. A. J. Barsky R. Saintfort M. P. Rogers J. F. Borus 2002 Nonspecific medication side effects and the nocebo phenomenon JAMA 287 5 622–627.
[6]. S. Stewart-Williams 2004 The placebo puzzle: putting together the pieces Health Psychol. 23 2 198–206.
[7]. I. Kirsch 2004 Conditioning, expectancy, and the placebo effect: comment on Stewart-Williams and Podd (2004) Psychol. Bull. 130 2 341–343.
[8]. S. Stewart-Williams J. Podd 2004 The placebo effect: dissolving the expectancy versus conditioning debate Psychol. Bull. 130 2 324–340.
[9]. M. E. Hyland B. Whalley A. W. A. Geraghty 2007 Dispositional predictors of placebo responding: a motivational interpretation of flower essence and gratitude therapy J. Psychosom. Res. 62 3 331–340.
[10]. J. Link R. Haggard K. Kelly D. Forrer 2006 Placebo/nocebo symptom reporting in a sham herbal supplement trial Eval. Health Prof. 29 4 394–406.
[11]. R. Thomson 1982 Side effects and placebo amplification Br. J. Psychiatry 140 64–68.
[12]. F. Benedetti M. Amanzio C. Casadio A. Oliaro G. Maggi 1997 Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide Pain 71 2 135–140.
[13]. S. Ross L. W. Buckalew 1985 Placebo agentry: assessment of drug and placebo effects L. White B. Tursky G. Schwartz Placebo -Theory, Research, and Mechanisms Guilford New York 67–82.
[14]. R. Brown 2006 Medically unexplained symptoms: a new model Psychiatry 5 2 43–47.
[15]. I. Kirsch 1997 Specifying nonspecifics: psychological mechanisms of placebo effects A. Harrington The Placebo Effect. An Interdisciplinary Exploration Harvard University Press Cambridge 166–186.
[16]. A. Geers S. Helfer K. Kosbab P. Weiland S. Landry 2005 Reconsidering the role of personality in placebo effects: Dispositional optimism, situational expectations, and the placebo response J. Psychosom. Res. 58 2 121–127.
[17]. J. M. Ferguson X. R. Alprazolam 1993 Patient acceptability, safety, and tolerability Psychiatr. Ann. 23 20–26.
[18]. J. W. Pennebaker 1994 Psychological bases of symptom reporting: perceptual and emotional aspects of chemical sensitivity Toxicol. Ind. Health 10 4 497–511.
[19]. E. Uhlenhuth P. E. Alexander G. Dempsey W. Jones B. S. Coleman A. M. Swiontek 1998 Medication side effects in anxious patients: Negative placebo responses? J. Affect. Disord. 47 1 183–190.
[20]. P. Spinhoven A. J. Willem van der Does 1997 Somatization and somatosensory amplification in psychiatric outpatients: An explorative study Compr. Psychiatry 38 2 93–97.
[21]. K. Kroenke 2006 Physical symptom disorder: a simpler diagnostic category for somatization-spectrum conditions J. Psychosom. Res. 60 4 335–339.
[22]. R. Keeley 2002 When are medication side effects due to the nocebo phenomenon? JAMA 287 19 2503.
[23]. Y. Nestoriuc E. J. Orav M. H. Liang R. Horne A. J. Barsky 2010 Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines Arthritis Care Res. 62 6 791–799.
[24]. A. J. Barsky G. Wyshak G. L. Klerman 1990 The Somatosensory Amplification Scale and its relationship to hypochondriasis J. Psychiatr. Res. 24 4 323–334.
[25]. J. Mailloux J. Brener 2002 Somatosensory amplification and its relationship to heartbeat detection ability Psychosom. Med. 64 2 353–357.
[26]. M. Nakao A. J. Barsky M. Nishikitani E. Yano K. Murata 2007 Somatosensory amplification and its relationship to somatosensory, auditory, and visual evoked and event-related potentials (P300) Neurosci. Lett. 415 2 185–189.
[27]. J. W. Pennebaker 1982 The Psychology of Physical Symptoms Springer New York.
[28]. A. J. Schmidt D. J. Wolfs-Takens J. Oosterlaan M. A. van den Hout 1994 Psychological mechanisms in hypochondriasis: attention-induced physical symptoms without sensory stimulation Psychother. and Psychosom. 61 1 117–120.
[29]. A. J. M. de Craen P. J. Roos A. L. de Vries J. Kleijnen 1996 Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness BMJ 313 7072 1624–1626.
[30]. D. E. Moerman 2002 Meaning, Medicine and the’ Placebo Effect’ Cambridge University Press Cambridge.
[31]. K. Schapira H. A. McClelland N. R. Griffiths D. J. Newell 1970 Study on the effects of tablet colour in the treatment of anxiety states Br. Med. J. 2 5707 446–449.
[32]. A. D. Cattaneo P. E. Lucchelli G. Filipucci 1970 Sedative effects of placebo treatment Eur. J. Clin. Pharmacol. 3 43–45.
[33]. F. Köteles G. Bárdos 2007 Tabletták várt hatása és színe/mérete közötti kapcsolatok Mentálhigiéné es Pszichoszomatika 8 4 277–290.
[34]. F. Köteles G. Bárdos 2009 Tabletták perceptuális jellemzői által generált mellékhatás-elvárások és pszichológiai hátterük Mentálhigiéné es Pszichoszomatika 10 1 47–62.
[35]. C. D. Spielberger R. L. Gorsuch R. E. Lushene 1970 Manual for the State-Trait Anxiety Inventory Consulting Psychologists Press Palo Alto, CA.
[36]. K. Sipos M. Sipos C. D. Spielberger 1994 A State-Trait Anxiety Inventory (STAI) magyar változata F. Mérei F. Szakács Pszichodiagnosztikai vademecum Nemzeti Tankönyvkiadó Budapest.
[37]. M. F. Scheier C. S. Carver M. W. Bridges 1994 Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): A reevaluation of the Life Orientation Test J. Pers. Soc. Psychol. 67 6 1063–1078.
[38]. S. Vautier E. Raufaste 2006 Configural instability of data from the Life Orientation Test — Revised Personality Individ. Differ. 40 8 1511–1518.
[39]. A. Geers K. Kosbab S. Helfer P. Weiland J. Wellman 2007 Further evidence for individual differences in placebo responding: an interactionist perspective J. Psychosom. Res. 62 5 563–570.
[40]. M. Bérdi F. Köteles 2010 Az optimizmus mérése: az Életszemlélet Teszt átdolgozott változatának (LOT-R) pszichometriai jellemzői hazai mintán Magyar Pszichológiai Szemle 65 2 273–294.
[41]. K. Kroenke R. L. Spitzer J. B. W. Williams 2002 The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms Psychosom. Med. 64 2 258–266.
[42]. A. Stauder B. Konkoly Thege 2006 Az észlelt stressz kérdőív (PSS) magyar verziójának jellemzői Mentálhigiéné és Pszichoszomatika 7 3 203–216.
[43]. F. Köteles H. Gémes G. Papp P. Túróczi A. Pásztor A. Freyler R. Szemerszky G. Bárdos 2009 A Szomatoszenzoros Amplifikáció Skála (SSAS) magyar változatának validálása Mentálhigiéné és Pszichoszomatika 10 4 321–335.
[44]. A. J. Barsky E. J. Orav D. K. Ahern M. P. Rogers S. D. Gruen M. H. Liang 1999 Somatic style and symptom reporting in rheumatoid arthritis Psychosomatics 40 5 396–403.
[45]. F. Köteles A. Tóth G. Bárdos 2011 Expectations of medicine adverse effects: Perceptual characteristics of tablets and personality background Clin. Exp. Med. J. 5 199–202.
[46]. F. Benedetti M. Lanotte L. Lopiano L. Colloca 2007 When words are painful: unraveling the mechanisms of the nocebo effect Neuroscience 147 2 260–271.
[47]. F. Köteles I. Komsa G. Bárdos 2010 The effect of perceptual characteristics of tablets upon patient's choice Clinical and Experimental Medical Journal 4 1 99–104.
[48]. S. C. Shea 2006 Improving Medication Adherence Lippincott Williams & Wilkins Philadelphia.
[49]. P. C. Gotzsche 1994 Is there logic in the placebo? Lancet 344 8927 925–926.